New Zealand markets open in 6 hours 37 minutes

Allarity Therapeutics, Inc. (ALLR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4110+0.0090 (+2.24%)
At close: 04:00PM EST
0.4245 +0.01 (+3.28%)
Pre-market: 08:59AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.4020
Open0.4060
Bid0.0000 x 1200
Ask0.0000 x 1200
Day's range0.3920 - 0.4199
52-week range0.3800 - 320.6000
Volume89,188
Avg. volume1,532,373
Market cap2.42M
Beta (5Y monthly)0.23
PE ratio (TTM)0.00
EPS (TTM)2,625.4299
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Allarity Therapeutics to Present at Biomarkers 2024

    Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024. Thomas Jensen, CEO and co-founder of Allarity, will present the company's novel work in developing the drug-specific Drug Response Predictor (DRP®) companion diagnostics (CDx) platform. This work spans from cancer cell lin

  • GlobeNewswire

    Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

    Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced a transition in its leadership. Effective immediately, James G. Cullem is no longer President and CEO. The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Ther

  • GlobeNewswire

    Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

    All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization change from once-daily to twice-daily Boston (December 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, toda